ERBB2 and adenocarcinoma: Thus, there is an opportunity for early clinical development of a HER2-targeting radiopharmaceutical in women with persistent, recurrent, or metastatic uterine cervix, perhaps in a trial enriched in design for adenocarcinomas or adenosquamous carcinomas (17).